A Phase III Study of Brimonidine Tartrate Ophthalmic Solution, 0.15% in Patients With Open-Angle Glaucoma or Ocular Hypertension

Alcon

Status and phase

Completed

Phase 3

Conditions

Open-Angle Glaucoma

Ocular Hypertension

Treatments

Drug: Brimonidine Tartrate Ophthalmic Solution

Study type

Interventional

Funder types

Industry

Identifiers

NCT00061529

C-02-49

Details and patient eligibility

About

The primary objective of this study is to compare the safety and efficacy of Brimonidine Tartrate Ophthalmic Solution, 0.15% in patients with open-angle glaucoma or ocular hypertension.

Sex

All

Ages

2+ months old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Patients of any race
two (2) years of age or older
of either sex
diagnosed with open-angle glaucoma (with or without pseudoexfoliation or pigment dispersion component)or ocular hypertension